Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations.
about
Calsequestrin 2 and arrhythmiasCatecholaminergic polymorphic ventricular tachycardia: An exciting new eraCurrent topics in catecholaminergic polymorphic ventricular tachycardiaCalsequestrin mutations and catecholaminergic polymorphic ventricular tachycardiaInherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesisDynamic, inter-subunit interactions between the N-terminal and central mutation regions of cardiac ryanodine receptorPrevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.Catecholaminergic polymorphic ventricular tachycardia: a current overview.Recent developments in the management of patients at risk for sudden cardiac death.Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndromeEffects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardiaImpaired calcium-calmodulin-dependent inactivation of Cav1.2 contributes to loss of sarcoplasmic reticulum calcium release refractoriness in mice lacking calsequestrin 2.Ryanodine receptor-mediated arrhythmias and sudden cardiac death.Ryanodine receptor dysfunction in arrhythmia and sudden cardiac death.Ryanodine receptor mutations in arrhythmia: The continuing mystery of channel dysfunction.The genetic and clinical features of cardiac channelopathies.Treatment of asymptomatic catecholaminergic polymorphic ventricular tachycardia.Calcium handling and ventricular tachyarrhythmias.Arrhythmia-associated cardiac Ca²(+) cycling proteins and gene mutations.Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.Choking-induced cardiac arrest unmasks a diagnosis of catecholaminergic polymorphic ventricular tachycardia.Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes.Catecholaminergic polymorphic ventricular tachycardia, an update.EHRA/HRS/APHRS expert consensus on ventricular arrhythmiasEHRA/HRS/APHRS expert consensus on ventricular arrhythmiasExecutive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia SyndromesHRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes
P2860
Q24300626-47282CA1-C632-436B-A4A5-E064F67D7897Q26747056-F02FBE17-5440-4967-BDF4-8B6784994983Q28076784-D3A92A5E-2D2F-46F5-8637-4C5EBB07083EQ28262015-94879B4C-45DD-499F-A2EF-E90097495D74Q28308142-61D9EC6E-D840-43B9-8452-06E0D6CB3E0DQ28589538-0EB58678-AD51-4B01-9811-F5255208A8A3Q30498471-2BF7D534-6B7B-49F0-B20C-66C75EAAE14AQ33157298-54B377E3-2D71-44DD-B264-7DD1C554D9B6Q33159915-607AEDB9-BA47-4350-A4C1-6D03744F13FDQ33160416-222E9E04-B7F7-4FB4-A7D0-2ABCF2E5BF27Q33161041-D797357C-3CB1-4ECC-8B5B-31CC157495E4Q33161560-53C6FF8F-16AD-4565-B37E-7647125BE9C4Q33162208-1E4EFB43-CCDB-49CC-A143-02B3A7A89824Q34629553-0C388866-7F97-4F03-93C5-3F08FC5515E0Q35514666-77C042CA-1122-4F17-A897-728F86903395Q37248371-7CA9CD5E-D09A-44B3-84F9-39A53A2ED105Q37608518-154A26B2-2601-4AEB-8714-6120DCF90FDBQ37687548-B732A3E3-8B40-4C9A-B311-C66649866EC7Q37770572-49AEE455-041E-4C38-BB58-1A29C712DADDQ38014115-0CC209A8-2FA9-4D5D-BE91-B5993C6A4719Q38016750-685BECC4-8225-41B0-9DE1-582003BA7246Q38021695-A7C5A482-78AF-40CF-B19C-319B733386C8Q38602828-16A96634-86FF-41DF-91BF-0C76B921EAC4Q39022381-C6279B82-2769-42D0-A197-708ACF5D9D48Q42081840-BA2D64B7-D3D5-43F0-901A-D1822C9573C4Q45027885-51D36168-173A-43B9-8018-7017520721E0Q48161835-8B2FA227-7011-4253-98CB-582E0F69DDB1Q57626635-43333CDD-AFEC-4C65-971A-4BE4C4E007C1Q57626770-868C4680-4CA7-4C24-A48D-B444D14ED5D7Q58010261-6BE0A3F0-9E08-4F2C-824A-E4B53C956B17Q58010282-4931DC18-887E-49C3-B7D2-D94C5D2F7E83
P2860
Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Calcium channel antagonism red ...... patients with RyR2 mutations.
@en
Calcium channel antagonism red ...... patients with RyR2 mutations.
@nl
type
label
Calcium channel antagonism red ...... patients with RyR2 mutations.
@en
Calcium channel antagonism red ...... patients with RyR2 mutations.
@nl
prefLabel
Calcium channel antagonism red ...... patients with RyR2 mutations.
@en
Calcium channel antagonism red ...... patients with RyR2 mutations.
@nl
P2093
P1476
Calcium channel antagonism red ...... patients with RyR2 mutations.
@en
P2093
Heikki Swan
Kimmo Kontula
Lauri Toivonen
Päivi Laitinen
P304
P356
10.1046/J.1540-8167.2005.40516.X
P577
2005-02-01T00:00:00Z